Treatment of early-stage Hodgkin's disease.
Semin Hematol
; 36(3): 270-81, 1999 Jul.
Article
em En
| MEDLINE
| ID: mdl-10462327
ABSTRACT
The management of early-stage Hodgkin's disease has been evolving over the past 25 years, largely due to recognition of early and late complications associated with radiation therapy and the demonstration of minimally toxic but effective chemotherapy. Thus, extended-field radiation is no longer the "gold standard" of treatment. Rather, combined modality approaches with abbreviated chemotherapy and limited radiation, which obviates the need for precise staging offered by laparotomy, provide excellent results with the potential for fewer adverse late effects. Several controlled clinical trials are ongoing to determine the minimal duration of chemotherapy and extent and dose of radiotherapy that will not compromise the excellent cure rate of early-stage disease.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Doença de Hodgkin
Limite:
Humans
Idioma:
En
Revista:
Semin Hematol
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos